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Background & aims: Nutrition is the major environmental factor that inﬂuences the risk of developing
pathologies, such as obesity. Although a number of recent reviews pinpoint a protective effects of milk on
body weight and obesity related co-morbidities, an inaccurate estimate of milk might contribute to
hamper its beneﬁcial effects on health outcomes. Seven-day food records provide prospective food intake
data, reducing recall bias and providing extra details about speciﬁc food items. Milk intake stimulates the
somatotropic axis at multiple levels by increasing both growth hormone (GH) and insulin-like growth
factor-1 (IGF-1) secretion. On the other hand, obesity is associated with reduced spontaneous and
stimulated GH secretion and basal IGF-1 levels. Aim of this study was to evaluate the milk consumption
by using the 7-days food record in obese individuals and to investigate the association between milk
intake and GH secretory status in these subjects.
Methods: Cross-sectional observational study carried out on 281 adult individuals (200 women and 81
men, aged 18e74 years) with moderate-severe obesity (BMI 35.2e69.4 kg/m2). Baseline milk intake data
were collected using a 7 day food record. Anthropometric measurements and biochemical proﬁle were
determined. The GH/IGF-1 axis was evaluated by peak GH response after GHRH þ ARGININE and IGF-1
standard deviation score (SDS).
Results: The majority of individuals (72.2%) reported consuming milk; 250 mL low-fat milk was the most
frequently serving of milk consumed, while no subjects reported to consume whole milk. Milk con-
sumers vs no milk consumers presented the better anthropometric measurements and metabolic proﬁle.
At the bivariate proportional odds ratio model, after adjusting for BMI, age and gender, milk consumption
was associated the better GH status (OR ¼ 0.60; p < 0.001). Among milk consumers, subjects consuming
250 mL reduced-fat milk vs 250 mL low-fat milk presented the better anthropometric measurements and
metabolic proﬁle. At the bivariate proportional odds ratio model, after adjusting for BMI, age and gender,
the consume of 250 mL reduced-fat milk was associated better GH status (OR ¼ 0.54; p ¼ 0.003).
Conclusions: A novel positive association between milk consumption, GH status, and metabolic proﬁle in
obese individuals was evidenced. Regardless of the pathogenetic mechanisms, this novel association might
be relevant in a context where commonly obese individuals skip breakfast, and suggests the need of a
growing cooperation between Nutritionists and Endocrinologists in themanagement of the obese patients.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).hormone; IGF-1, insulin-like growth factor 1; IGF-1 (SDS), insulin-like growth factor 1 standard deviation score; SBP,
; PTH, parathyroid hormone; HoMA-IR, homeostasis model assessment e insulin resistance; HDL, High-density lipo-
aminotransferase; ALT, Alanine transaminase; gGT, g-glutamyltransferase; MetS, metabolic syndrome.
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Nutrition is the major environmental factor, directly under hu-
man control, that interacts with genetic predisposition and in-
ﬂuences the risk of developing pathologies, such as obesity and
diabetes. Milk, with cheese and yogurt, is one of the three most
commonly consumed dairy products. Most countries have quanti-
tative recommendations that usually range from 2 to 3 servings or
cups of milk or yogurt or sometimes the equivalent serving of
cheese [1]. In Italy it is recommended to consume per day 250mL of
milk [2]. A number of recent reviews pinpoint a protective effects of
dairy products on health outcomes [1], body weight [3] and obesity
related co-morbidities, including type 2 diabetes and cardiovas-
cular disease [4,5]. However, the relative contribution of the
nutritional components of milk in these associations still remains
inconclusive. In addition, milk consumption is often targeted in
obese individuals to reduce saturated fatty acids, the intake of
which is commonly discouraged in current dietary guidelines [6];
moreover, eating behavior in obese individuals is often character-
ized per se by skipping breakfast [7], traditionally the main meal of
the day where Italians mostly consume milk [8].
A possible source of uncertainty in the beneﬁcial effects of milk
in the vast majority of the studies might result from an inaccurate
estimate of milk intake due to the use of retrospective methods of
dietary assessment or from too demanding food frequency ques-
tionnaires. By contrast, 7-days food record provide prospective food
intake data. In particular, 7-days food diary are recorded at the
same time of consumption, reduce the recall bias and provide extra
details about the types and amounts of speciﬁc food items.
Recently, a prospective study using dietary data from 7-days food
record reported the association between the consumption of spe-
ciﬁc dairy products and a decreased risk of type 2 diabetes [4].
Several studies have consistently shown that high milk intake
exerts relevant effects on somatotropic axis, an integrated endo-
crine system also involved in body weight balance [9]. In particular,
milk intake stimulates the somatotropic axis at multiple levels by
increasing both growth hormone (GH) and insulin-like growth
factor-1 (IGF-1) secretion [10e12]. On the other hand, obesity is
associated with reduced spontaneous and stimulated GH secretion
and basal IGF-1 levels [13]. Both central and peripheral factors
might account for this condition of functional low GH status in
obesity, including nutritional-driven components, insulin-glucose
homeostasis, and circulating free fatty acids (FFA) [14]. Currently,
no studies on the regulation of the somatotropic axis by dietary
factors, mainly milk intake, were carried out using a dynamic
evaluation of GH secretion and the 7-days food record in obesity.
The aims of this study are twofold. Firstly, to evaluate the intake,
frequency, and type of milk consumed, derived from the 7-days
food record in obese individuals. Secondly to investigate the asso-
ciation between milk intake and GH secretory status in these
subjects.2. Materials and methods
2.1. Subjects and methods
2.1.1. Design and setting
This is a cross-sectional observational study carried out at the
Department of Clinical Medicine and Surgery of the University of
Naples Federico II (Italy) from July 2013 to February 2015. The
procedures used were in accordance with the guidelines of the
Helsinki Declaration on human experimentation. The study was
approved by the Ethics Committee of the Federico II University
Medical School of Naples (n.5/14). The purpose of the protocol wasclearly explained to all the participants. The study was conducted
without support from the pharmaceutical industry.
2.1.2. Population study
After obtaining written informed consent, 421 adult individuals
(>18 years of age), who were referred to our unit for bariatric
surgery evaluation, were consecutively enrolled. Criteria for
exclusion from the study were current use of medications affecting
calcium homeostasis and fat metabolism, including calcium and
vitamin D (8 subjects), corticosteroids (10 subjects), antacids and
proton pump inhibitors (15 subjects), bile-acid sequestrants and
lipase inhibitors (7 subjects). Moreover, individuals with concur-
rent medical illness, such as neoplastic diseases (1 subject), renal
diseases (2 subjects), malabsorptive disorders (5 subjects), in-
ﬂammatory bowel diseases (9 subjects) and lactose intolerance (15
subjects), were excluded. Finally, we excluded from the study
subjects following a speciﬁc dietary regimen for any reason (2
vegan subjects), those reporting to eat dairy foods more than once
per week (55 subjects), and those drinking special milks, such as
goat's and soy milk, and fermented milk as keﬁr and yoghurt (11
subjects).
Therefore, a total of 281 participants (200 women and 81 men,
aged 18e74 years) with moderate-severe obesity (Body Mass Index
(BMI): 35.2e69.4 kg/m2), remained for analysis.
2.1.3. Dietary assessment
Dietary assessment and baseline milk intake datawere collected
using a 7 day food record [15,16]. Milk consumption was estimated
using photographs representing portion sizes and household
measures. The day one of the diary nutritionists trained to stand-
ardised protocols provided participants with instructions on how to
complete the diary at the health check and asked participants to
recall the previous day's intake. Participants prospectively
completed the remaining 6 days. The subjects returned the records
to the nutritionist who asked supplemental questions, if necessary.
From these records the total amount of milk consumed was esti-
mated, being the sum of the milk taken in milk containing drinks
and with breakfast cereals. According to the Italy Food Guide Pyr-
amid [2], the reference serving size of milk is 125 mL, equal to a
glass of milk. It is recommended per day to consume 250mL of milk
(2 reference amounts).
The milk consumption was evaluated as: 1. Consumption (yes/
no); 2. Type of milk consumed (whole milk, reduced-fat milk, and
low-fat milk); 3. Serving of milk consumed (small serving, 125 mL;
regular serving, 250 mL and large serving, 375 mL). 4. Daily average
of total milk consumed during the seven days (<250 mL/
day, ¼250 mL/day, >250 mL/day); 5. Consumption and type of milk
(250 mL reduced-fat milk daily/other servings and types of milk).
Data were stored and processed using a commercial software
(Terapia Alimentare Dietosystem® DS-Medica, http://www.
dsmedica.info). The data were also compared with the tables of
food consumption and recommended dietary intakes of the BDA
(Food Composition Database for Epidemiological Studies in Italy)
Italian National Institute of Nutrition and Food Composition Data-
base in Italy (www.inran.it).
2.1.4. Anthropometric measurements
All anthropometric measurements were taken with subjects
wearing only light clothes and without shoes. In each subject,
weight and height weremeasured to calculate the BMI [weight (kg)
divided by height squared (m2), kg/m2]. Height was measured to
the nearest 1 cm using a wall-mounted stadiometer. Body weight
was determined to the nearest 50 g using a calibrated balance beam
scale. Waist Circumference (WC) was measured to the closest
0.1 cmwith a non-extensible tape at the natural indentation or at a
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cage if no natural indentation was visible. The measurement was
made with the subject standing upright, feet together and arms
hanging freely at the sides, with the subjects standing and
breathing normally. In all individuals were measured Systolic (SBP)
and diastolic (DBP) blood pressure in three times, 2 min apart, with
a random zero sphygmomanometer (Gelman Hawksley Ltd., Sus-
sex, UK) after the subject had been sitting for at least 10 min. The
average of the second and third reading was recorded.
Information on smoking habit, alcohol consumption, and
physical activity was obtained by a standard questionnaire. Current
smokers were deﬁned as those who smoked at least one cigarette
per day and former smokers as those who had stopped smoking
more than 1 year before the interview; the rest of the participants
were deﬁned as noncurrent smokers. Participants were also clas-
siﬁed according to their alcohol intake into two groups: at least one
glass of wine (or an equivalent amount of other alcoholic beverages
per day) (YES) or no alcohol consumption (NO). Physical activity
level was expressed according to whether the participant habitu-
ally engaged at least 30 min/day of aerobic exercise (YES/NO).
2.1.5. Deﬁnition of conventional risk factors
Obesity: The degree of obesity was established according to a
scale based on BMI cut-off points: 35e39.9 kg/m2 (grade II obesity
or moderate obesity) and 40 kg/m2 (grade III obesity or severe
obesity), respectively. Abdominal obesity was deﬁned as:
WC  102 cm in men and 88 cm in women. Hypertension was
deﬁned as: SBP  140 mmHg or DBP  90 mmHg on two different
occasions or taking antihypertensive medication. Hyper-
cholesterolaemia was deﬁned as: a fasting blood total cholesterol
level 190 mg/dL or use of lipid-lowering medication, and hyper-
triglyceridaemia as fasting blood triglyceride levels 150 mg/dL or
use of lipid-lowering medication [17]. Diabetes: A history of using
hypoglycemic agents or a type 2 diabetes was diagnosed according
to ADA criteria [18].
2.1.6. Criteria to deﬁne metabolic syndrome
According to the National Cholesterol Education Program Adult
Treatment Panel (NCEP ATP) III deﬁnition, metabolic syndrome
(MetS) is present if three or more of the following ﬁve criteria are
met: WC  102 cm (men) or 88 cm (women), blood pressure130/
85 mmHg, fasting triglyceride level 150 mg/dL, fasting high-
density lipoprotein (HDL) cholesterol level 40 mg/dL (men) or
50 mg/dL (women), and fasting glucose  100 mg/dL [19].
2.1.7. Biochemical measurements
Samples were collected between 8 and 10 a.m. after an over-
night fast of at least 8 h, with the individuals were in the resting
position, and stored at 80 C until being processed. All
biochemical analyses including fasting plasma glucose, total
cholesterol, fasting plasma triglycerides, total proteins and albu-
min, total calcium, creatinine, aspartate aminotransferase (AST),
alanine transaminase (ALT), g-glutamyltransferase (gGT) were
performed with a Roche Modular Analytics System in the Central
Biochemistry Laboratory of our Institution. Low-density lipoprotein
(LDL) and HDL cholesterol were determined by direct method
(homogeneous enzymatic assay for the direct quantitative deter-
mination of LDL and HDL cholesterol). Corrected serum calcium
was calculated (corrected calcium [mg/dL] ¼ serum calcium [mg/
dL] þ 0.8 [4serum albumin [g/dL]]). Intact parathyroid hormone
(PTH) was measured by immunometric assay (Immulite iPTH;
Diagnostic Products, Los Angeles, CA); the intra- and interassay CV
were <7.0% and <5.5%, respectively. Fasting insulin levels were
measured by a solid-phase chemiluminescent enzyme immuno-
assay using a commercially available kits (Immunolite DiagnosticProducts Co, Los Angeles, CA). The intra-assay coefﬁcients of vari-
ations (CV) for insulin was <5.5%. Homeostasis Model Assessment
of Insulin Resistance (HoMA-IR) was calculated according to Mat-
thews et al. [20]: a value of HoMA-IR >2.0 was set as stringent
measure of insulin resistance.
The GH/IGF-1 axis was evaluated by measuring the GH peak
after GHRHþ ARGININE (ARG) and assay of circulating IGF-1 levels.
The GH releasing hormone (RH) (1e29, Geref, Serono, Rome,
Italy) þ ARG (arginine hydrochloride, Salf, Bergamo, Italy) was
performed according to Ghigo et al. [21] The GH response after
ARG þ GHRH was classiﬁed as deﬁcient (GHD) when the GH peak
was 4.2 mg/L and sufﬁcient (GHS) when the GH peak was4.2 mg/
L [22]. Serum GH levels were measured by immunoradiometric
assay (IRMA) using commercially available kits (HGH-CTK-IRMA,
Sorin, Saluggia, Italy). The sensitivity of the assay was 0.02 mg/L. The
intra- and interassay coefﬁcients of variations (CVs.) were 4.5% and
7.9%, respectively. IGF-1 levels were classiﬁed as deﬁcient when the
standard deviation score (SDS) from the meanwas <e2 for age and
gender and sufﬁcient when the SDS ranged from >e2 to 2.24 [23].
Serum IGF-1 levels were measured by IRMA after ethanol extrac-
tion (DSL Inc, Webster, TX); assay sensitivity was 0.8 mg/L; the
normal ranges in adults aged 20e40 and 41e60 years were
110e494 and 100e300 mg/L, respectively. The intra-assay CVs. were
3.4%, 3.0% and 1.5% for the low, medium and high points of the
standard curve, respectively. The interassay CVs. were 8.2%, 1.5%
and 3.7% for the low, medium and high points of the standard
curve, respectively.
2.1.8. Statistical analysis
Results are expressed as mean ± SD or as median plus range
according to variable distributions evaluated by Kolmogor-
oveSmirnov test (p < 0.001). Differences between groups were
analyzed by unpaired t test or ManneWhitney U-test, as appro-
priate. When more than two groups were compared, analyses of
variance (ANOVA) or KruskaleWallis test were performed, as
appropriate, followed by Bonferroni post hoc analysis. The chi
square (c2) test was used to determine the signiﬁcance of differ-
ences in frequency distributions. Proportional odds ratio (OR)
models were performed to assess the association among quanti-
tative variables and qualitative variables (milk consumption: yes/
no; type of milk: reduced-fat/low-fat milk; amount/type milk
consumption: 250 mL reduced-fat milk/250 mL low-fat milk and
servings of milk consumption: 125/250/375 mL). In these analyses,
we entered only those variables that had a p value < 0.05 in the
univariate analysis. To avoid multicollinearity, variables with a
variance inﬂation factor (VIP) > 10 were excluded. Values  5%
were considered statistically signiﬁcant. Data were stored and
analyzed using the MedCalc® package (Version 12.3.0 1993e2012
MedCalc Software bvbaeMedCalc Software, Mariakerke, Belgium).
Proportional odds model was carried out using the R Project for
Statistical Computing 2014 (http://www.R-project.org).
3. Results
A higher percentage of obese participants were non-smokers
(72%), non-alcohol users (82%), and sedentary (80%). Socio-
demographic, anthropometric and metabolic characteristics of
281 obese individuals included in the study are summarized in
Table 1. The majority of participants presented severe obesity and
were females. In particular, 55 individuals (19.6%) were moderately
obese and 226 individuals (80.4%) were severely obese. According
to peak GH response and IGF-1 SDS,169 individuals (60.1%) and 194
individuals (69.0%) presented GHD and IGF-1 deﬁciency, respec-
tively. Impaired fasting glucose was diagnosed in 24.2% (68 pts),
type 2 diabetes in 39.1% (110 pts), HoMA-IR >2 in 77.9% (219 pts),
Table 1
Socio-demographic, anthropometric measures and metabolic proﬁle of 281 obese
patients included in the study.
Parameters
Age (years) 37.1 ± 12.1
Gender (Females) 200 (71.2%)
BMI (kg/m2) 44.1 (35.2e69.4)
Peak GH response (mg/L) 2.5 (0.1e18.6)
IGF-1 (mg/L) 138.0 (35.0e483.0)
IGF-1 (SDS) 2.7 (6.1 to 5.9)
Waist circumference (cm) 130.8 ± 17.8
SBP (mmHg) 130.0 (80.0e180.0)
DBP (mmHg) 80.0 (50.0e110.0)
Total Calcium (mg/dL) 9.4 ± 0.5
Corrected Calcium (mg/dL) 9.0 ± 0.5
PTH (pg/mL) 48.0 (15.6e138.0)
Fasting Glucose (mg/dL) 94.0 (61.0e299.0)
Fasting Insulin (mU/mL) 18.0 (4.7e63.4)
HoMA-IR 4.2 (0.8e38.7)
Creatinine (mg/dL) 0.7 (0.5e1.4)
Serum albumin (g/dL) 4.5 ± 0.3
Total serum proteins (g/dL) 7.5 (6.0e8.8)
Total cholesterol (mg/dL) 186.4 ± 45.6
HDL cholesterol (mg/dL) 48.0 (10.0e98.0)
LDL cholesterol (mg/dL) 106.4 ± 46.8
Fasting Triglycerides (mg/mL) 149.0 (44.0e583.0)
AST (U/L) 29.0 (7.0e153.0)
ALT (U/L) 37.0 (5.0e202.0)
gGT (U/L) 36.0 (8.0e242.0)
The majority of participants presented severe obesity and were females. Results are
expressed as mean ± SD or as median plus range according to variable distributions
evaluated by KolmogoroveSmirnov test. BMI, body mass index; GH, growth hor-
mone; IGF-1, insulin-like growth factor 1; IGF-1 (SDS), insulin-like growth factor 1
standard deviation score; SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; PTH, parathyroid hormone;HoMA-IR, homeostasismodel assessment - insulin
resistance; HDL, High-density lipoprotein; LDL, low-density lipoprotein; AST,
aspartate aminotransferase;ALT, Alanine transaminase; gGT, g-glutamyltransferase.
Table 2
Anthropometric measures and metabolic proﬁle of 281 obese patients according to GH s
Parameters GH e IGF-1 deﬁcit GHe
n ¼ 146 (52%) n ¼
Age (years) 35.9 ± 11.3 40.0
BMI (kg/m2) 47.6 (36.2e67.6) 40.0
Waist circumference (cm) 135.9 ± 17.5 119
SBP (mmHg) 130.0 (90.0e180.0) 120
DBP (mmHg) 85.0 (60.0e110.0) 62.5
Peak GH response (mg/L) 0.2 (0.0e4.1) 7.9
IGF-1 (mg/L) 115.0 (35.0e183.0) 235
IGF-1 (SDS) 3.3 (6.1 to 2.0) 6.
PTH (pg/mL) 59.4 (15.8e138.0) 39.4
Total Calcium (mg/dL) 9.4 ± 0.5 9.5
Corrected Calcium (mg/dL) 9.0 ± 0.5 9.1
Fasting Glucose (mg/dL) 106.0 (68.0e269.0) 85.0
Fasting Insulin (mU/mL) 24.3 (5.0e61.5) 9.1
HoMA-IR 6.5 (1.0e38.7) 1.9
Creatinine (mg/dL) 0.7 (0.5e1.3) 0.7
Serum albumin (g/dL) 4.4 ± 0.3 4.4
Total serum protein (g/dL) 7.4 (6.0e8.6) 7.7
Total cholesterol (mg/dL) 194.2 ± 45.8 174
HDL cholesterol (mg/dL) 45.5 (25.0e98.0) 53.5
LDL cholesterol (mg/dL) 114.7 ± 47.4 92.9
Fasting Triglycerides (mg/dL) 155.0 (44.0e480.0) 144
AST (U/L) 30.0 (8.0e116.0) 28.5
ALT (U/L) 33.0 (9.0e199.0) 42.5
gGT (U/L) 41.0 (11.0e232.0) 29.0
MetS (n, %) 92 (63.0%) 14 (
The majority of obese subjects were GHD and IGF-1 insufﬁcient. As expected, this sub
Metabolic syndrome was diagnosed according to the NCEP ATP III (ref# 19 in the text).
distributions evaluated by KolmogoroveSmirnov test. Differences between groupswere a
was used to determine signiﬁcance differences in frequency distributions of MetS. A p valu
systolic blood pressure; DBP, diastolic blood pressure; GH, growth hormone; IGF-1, insu
score; PTH, parathyroid hormone; HoMA-IR, homeostasis model assessment - insulin res
aminotransferase; ALT, Alanine transaminase; gGT, g-glutamyltransferase; MetS, metab
L. Barrea et al. / Clinical Nutrition 36 (2017) 293e301296hypertension in 35.2% (99 pts) and MetS in 47.3% (133 pts). Socio-
demographic, anthropometric measurements and metabolic char-
acteristics of 281 obese participants according to GH status are
reported in Table 2. As expected, obese individuals with both GHD
and IGF-1 deﬁciency (146 pts), presented the worst anthropometric
measurements and metabolic proﬁle compared with obese coun-
terparts with normal peak GH response (64 pts) or with those with
GH/IGF-1 discordance (71 pts).
Figure 1 shows the milk intake in our group of obese partici-
pants. Among obese individuals, only less than 1/3 of participants
reported not consuming milk and skipping breakfast. By contrast,
the majority of individuals (203 pts) reported consuming milk; in
particular, 250 mL low-fat milk was the most frequently serving of
milk consumed, while no subjects reported to consumewholemilk.
In addition, breakfast was the only meal time where participants
reported consuming milk servings, while there were no gender
differences in types or amounts of milk consumption (p ¼ 0.461
and p ¼ 0.974, respectively). Total energy intake was not signiﬁ-
cantly different between milk consumers and no milk consumers
(2289.0 ± 355.9 vs 2308.2 ± 454.8 kcal; p ¼ 0.712).
The peak GH responsewas sufﬁcient in 52.2%milk consumers vs
7.7% no milk consumers (c2 ¼ 44.76; p < 0.001). Table 3 summa-
rizes the clinical characteristics of milk consumers according to
milk servings. The best anthropometric measurements and meta-
bolic proﬁle were observed in subgroup of obese individuals
consuming 250 mL servings of milk. In addition, this subgroup
presented the highest peak GH response and IGF-1 SDS. In partic-
ular, the peak GH response was sufﬁcient in 71.4% consumers of
250 mL milk vs 32.4% and 50.9% consumers of < or >250 mL milk,
respectively (c2¼ 22.61; p < 0.001). Table 4 summarizes the clinical
characteristics of the consumers of 250 mL of milk according to
milk type. As seen in Table 4, the subgroup of the consumers oftatus.
IGF-1 sufﬁciency GH/IGF-1 discordance p-value
64 (23%) n ¼ 71 (25%)
± 13.0 37.1 ± 12.1 0.073
(35.2e69.4) 43.7 (35.2e58.2) <0.001
.7 ± 16.6 130.4 ± 14.8 <0.001
.0 (100.0e170.0) 130.0 (80.0e180.0) <0.001
(60.0e110.0) 80.0 (50.0e100.0) <0.001
(4.2e18.6) 4.7 (0.1e17.0) <0.001
.5 (132.4e231.0) 159.0 (56.4e483.0) <0.001
2 (2.0 to 5.9) 2.4 (4.9 to 2.9) <0.001
(20.0e109.0) 42.8 (15.6e106.0) 0.004
± 0.5 9.5 ± 0.4 0.121
± 0.5 9.0 ± 0.4 0.519
(61.0e243.0) 94.0 (61.0e299.0) <0.001
(4.7e63.4) 15.8 (15.0e46.3) <0.001
(0.8e38.0) 3.6 (1.0e20.7) <0.001
(0.5e1.1) 0.8 (0.5e1.4) 0.063
± 0.4 4.5 ± 0.3 0.403
(6.1e8.8) 7.5 (6.0e8.7) 0.007
.3 ± 47.6 181.3 ± 40. 0.008
(27.0e72.0) 49.0 (10.0e85.0) 0.004
± 48.7 101.6 ± 40.3 0.005
.5 (53.0e256.0) 141.0 (50.0e583.0) 0.097
(7.0e101.0) 29.0 (7.0e153.0) 0.750
(5.0e177.0) 37.0 (6.0e202.0) 0.172
(8.0e108.0) 35.0 (13.0e242.0) 0.004
21.9%) 27 (38.0%) <0.001
group presented the worst anthropometric measurements and metabolic proﬁle.
Results are expressed as mean ± SD or as median plus range according to variable
nalyzed by ANOVA or KruskaleWallis test, when appropriate. The chi square (c2) test
e in bold type denotes a signiﬁcant difference (p < 0.05). BMI, body mass index; SBP,
lin-like growth factor 1; IGF-1 (SDS), insulin-like growth factor 1 standard deviation
istance; HDL, High-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate
olic syndrome.
Fig. 1. Milk intake in 281 obese patients. Among obese patients milk was consumed by the majority of subjects (203 pts); in particular, 250 mL low-fat milk was the serving most
frequently consumed. No subjects reported to consume whole milk. Results are expressed as percentage. Small serving, 125 mL; Regular serving, 250 mL; Large serving, 375 mL.
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anthropometric measurements and GH status comparedwith those
consuming low-fat milk. In particular, the peak GH response was
sufﬁcient in 78.8% consumers of 250 mL reduced-fat milk vs 27.3%
consumers of 250 mL low-fat milk (c2 ¼ 9.87; p ¼ 0.002).
Figure 2 shows the peak GH response and IGF-1 SDS levels in the
study population grouped according to the amount of milk con-
sumption and BMI. In both patients with moderate and severe
obesity the prevalence of individuals with a normal peak GH
response and normal IGF-1 SDS levels were higher among in-
dividuals consuming the 250 mL serving of milk compared with
those consuming different servings.
3.1. Correlation studies
A bivariate proportional odds ratio model was performed to
assess the association of milk consumption (yes/no) with anthro-
pometric measures and metabolic proﬁle. As expected, milk con-
sumptionwas associatedwith anthropometric measurements, SBP/
DBP, PTH, total calcium and corrected calcium, HoMA-IR, lipid
proﬁle, ALT, gGT and MetS (Table 5). Table 6 shows the multivariate
proportional odds ratio model performed to assess the association
among three different servings of milk with the GH status. Ac-
cording to the servings of milk, after adjusting for BMI, age and
gender, the subjects consuming 250 mL presented the best GH
status. Table 7 shows the bivariate proportional odds ratio models,
performed to assess the association of milk consumption (yes/no;
model 1) and type of milk (reduced-fat/low-fat milk; model 2),with the GH status. The subjects consuming milk, in particular
reduced-fat milk have higher peak GH response and IGF-1 SDS than
those not consuming milk or consuming low-fat milk, after
adjusting for BMI, age and gender. Table 8 gives the bivariate pro-
portional odds ratio model performed to assess the association of
250mL reduced-fat milk or 250mL low-fat milk. After adjusting for
BMI, age and gender, subjects consuming 250 mL reduced-fat milk
have higher peak GH response and IGF-1 SDS than those consuming
250 mL low-fat milk.
4. Discussion
In this observational study using the dietary intake data from 7-
days food record, we found that in our series of obese Italian adults
less than 1/3 of participants reported not consuming milk and
skipping breakfast. In line with the Italian guidance [2], the 250 mL
of milk was consumed by the majority of the participants. In
particular, 250 mL reduced-fat milk was most frequently consumed
serving of milk, breakfast was the only meal time where partici-
pants reported consuming milk, and there were no gender differ-
ences in milk consumption. As novel ﬁndings, using a dynamic
evaluation of GH secretion, we found that among milk consumers
peak GH response was sufﬁcient in more than one-half of partici-
pants, despite obese individuals are frequently characterized by a
functional low GH status. In particular, after adjusting for BMI, age
and gender, the subgroup of obese individuals consuming 250 mL
reduced-fat milk presented the best metabolic proﬁle, anthropo-
metric measurements, and GH status.
Table 3
Anthropometric measures and metabolic proﬁle of 203 obese patients according to amount of milk consumption (<250 mL/250 mL/>250 mL).
Parameters <250 mL 250 mL >250 mL p value
71 (25.3%) 77 (27.4%) 55 (19.6%)
Age (years) 35.1 ± 10.5 37.1 ± 11.2 37.1 ± 14.1 0.369
BMI (kg/m2) 44.4 (35.2e58.8) 40.4 (35.2e51.9) 43.1 (35.9e54.5) <0.001
Waist circumference (cm) 130.2 ± 17.0 121.9 ± 14.7 126.7 ± 13.2 0.004
SBP (mmHg) 130.0 (95.0e160.0) 120.0 (80.0150.0) 130.0 (100.0e160.0) 0.019
DBP (mmHg) 80.0 (50.0e110.0) 80.0 (60.0e100.0) 80.0 (60.0e110.0) 0.015
Peak GH response (mg/L) 2.7 (0.1e14.8) 6.9 (0.1e18.0) 4.6 (0.1e18.6) <0.001
IGF-1 (mg/L) 140.0 (35.0e270.0) 199.0 (67.0e483.0) 138.0 (50.0e304.0) <0.001
IGF-1 (SDS) 2.8 (5.4 to 0.4) 1.5 (4.1 to 5.9) 2.8 (6.1 to 2.4) <0.001
PTH (pg/ml) 42.0 (16.1e116.0) 44.3 (15.6e109.0) 34.6 (19.0e123.0) 0.117
Total Calcium (mg/dl) 9.5 ± 0.4 9.5 ± 0.4 9.7 ± 0.4 0.002
Corrected Calcium (mg/dL) 9.1 ± 0.4 9.0 ± 0.4 9.3 ± 0.3 <0.001
Fasting Glucose (mg/dL) 94.0 (61.0e142.0) 85.0 (61.0e243.0) 91.0 (73.0e269.0) 0.001
Fasting Insulin (mU/mL) 16.4 (5.0e44.5) 11.2 (4.7e46.3) 14.5 (5.0e58.3) 0.055
HoMA-IR 3.8 (1.1e15.5) 2.4 (0.8e20.9) 3.2 (1.0e38.7) 0.027
Creatinine (mg/dL) 0.8 (0.5e1.1) 0.8 (0.5e1.1) 0.7 (0.5e1.2) 0.186
Serum albumin (g/dL) 4.4 ± 0.3 4.5 ± 0.3 4.5 ± 0.3 0.514
Total serum protein (g/dL) 7.7 (6.3e8.6) 7.8 (6.9e8.8) 7.8 (6.3e8.7) 0.865
Total cholesterol (mg/dL) 185.3 ± 43.1 174.8 ± 42.2 185.7 ± 36.2 0.200
HDL cholesterol (mg/dL) 49.0 (31.0e98.0) 51.0 (27.0e75.0) 50.0 (25.0e75.0) 0.977
LDL cholesterol (mg/dL) 103.7 ± 43.8 96.8 ± 44.7 105.4 ± 37.9 0.462
Fasting Triglycerides (mg/dL) 152.0 (63.0e480.0) 126.0 (44.0e583.0) 147.0 (92.0e264.0) 0.064
AST (U/L) 29.0 (7.0e116.0) 27.5 (7.0e91.0) 30.0 (8.0e109.0) 0.550
ALT (U/L) 37.0 (5.0e96.0) 38.5 (6.0e202.0) 33.0 (9.0e199.0) 0.776
gGT (U/L) 34.0 (12.0e95.0) 33.0 (8.0e242.0) 34.0 (11.0e155.0) 0.930
MetS (n, %) 32 (45.7%) 22 (28.6%) 22 (39.3%) 0.105
The best anthropometric measurements and metabolic proﬁle were observed in subgroup of patients consuming a 250 mL of milk. In addition, this subgroup presented the
highest peak GH response and IGF-1 SDS. In particular, the peak GH response was sufﬁcient in 71.4% consumers of 250 mLmilk vs 32.4% and 50.9% consumers of < or >250 mL
milk, respectively (c2 ¼ 22.61; p < 0.001). Results are expressed as mean ± SD or as median plus range according to variable distributions evaluated by KolmogoroveSmirnov
test. Differences between groupswere analyzed by ANOVA or KruskaleWallis test, when appropriate. The chi square (c2) test was used to determine signiﬁcance differences in
frequency distributions of MetS. A p value in bold type denotes a signiﬁcant difference (p < 0.05). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; GH, growth hormone; IGF-1, insulin-like growth factor 1; IGF-1 (SDS), insulin-like growth factor 1 standard deviation score; PTH, parathyroid hormone; HoMA-IR,
homeostasis model assessment - insulin resistance;HDL, High-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, Alanine transaminase;
gGT, g-glutamyltransferase; MetS, metabolic syndrome.
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individuals the milk consumption by the use of prospective 7-days
food diary record and the somatotropic axis functional testing, by
the use of a dynamic evaluation of GH secretion and IGF-1 levels
standardized for age and sex. To the best of our knowledge this is
the ﬁrst study reporting the positive association between milk
consumption and somatotropic axis in obesity.
As expected, in our study we found that milk consumption was
correlated positively with total calcium and negatively with BMI.
The inverse association between calcium intake and body weight
was originally described almost 30 years ago, in a study on the
relationship between nutrient intake and blood pressure by
McCarron et al. [24]. This observation was subsequently conﬁrmed
by Trevisan et al. [25] while evaluating the inverse relationship
between BMI and the frequency of consumption of milk in Italian
male adults. Finally, Zemel et al. [26], by analyzing data from Na-
tional Health and Nutrition Examination Survey (NHANES) III,
demonstrated a profound reduction in the odds of being in the
highest quartile of adiposity associated with increases in calcium
and dairy product intake.
In addition to being a major source of dietary calcium, milk is
rich in speciﬁc amino acids that may have strong inﬂuence on IGF-1
levels. The primary stimulator of IGF-1 secretion is GH, with a ﬁne
modulation by IGF-binding proteins (BP), primarily IGFBP-3 [9].
IGF-1 levels represents also a stable and integratedmeasurement of
GH production and its peripheral effects. However, IGF-1 levels are
also nutritionally regulated, with a positive association between
milk intake in both childhood and adulthood [27,28]. In particular,
both energy and protein are critical to the regulation of serum IGF-1
levels [29]. Data from the European Prospective Investigation into
Cancer and Nutrition (EPIC), reported a 2.5% and 2.4% increase inIGF-1 per 3% and 2% increase in energy from total protein and dairy,
respectively [30]. In addition, IGF-1 contained in cow's milk is
structurally identical to human IGF-1; however it is generally
believed that the bioactivity of milk-derived IGF-1 is lost because of
rapid proteolysis in the upper gut [31]. Thus, the physiologic basis
for the positive association between milk intake and circulating
IGF-1 levels, especially considering the GH status, remains unclear.
Rich-Edwards et al. [32] found that milk drinking may cause
increases in GH levels of prepubertal children. However, consid-
ering the pulsatile nature of GH secretion, the assessment of GH
secretion requires the use of pharmacological challenges, such
GHRH þ ARGININE. This test, currently considered the favourite
diagnostic tool due to its high speciﬁcity and sensitivity, as well as
tolerability [33]. GHRH þ ARGININE challenge is also the only test
for which BMI-dependent variability of GH responsiveness has
been investigated [34], with the deﬁnition of 4.2 mg/L as the
appropriate GH cut-off in adults with BMI 30 kg/m2 [22]. Using
this new cut-off value of the GHRH þ ARGININE test, about 1/3
morbidly obese individuals, without any evidence of organic pitu-
itary disease, presented a low peak stimulated GH [35]. Of interest,
changes in the cardiovascular risk proﬁle and body composition in
obese individuals with low GH status are associated with increased
cardio-metabolic sequelae [36]. In the present study, the evaluation
of GH status allowed us to better deﬁne the relationship between
milk and somatotropic axis, as we found that milk consumption is
positively associated not only with IGF-1 levels, but also with
stimulated GH secretion. In addition, the subgroup of obese in-
dividuals with the highest intake of milk presented the lowest BMI
and best metabolic proﬁle.
Several mechanisms to explain the association between higher
milk consumption and lower BMI have been suggested. Possible
Table 4
Anthropometric measures and metabolic proﬁle of 77 obese patients consuming
250 mL milk according to milk type.
Parameters 250 mL low-fat
milk
250 mL reduced-fat
milk
p value
n ¼ 11 (3.9%) n ¼ 66 (23.5%)
Age (years) 38.5 ± 11.0 36.8 ± 11.3 0.636
BMI (kg/m2) 45.6 (41.5e51.9) 40.1 (35.2e46.7) <0.001
Waist circumference (cm) 133.8 ± 15.3 119.9 ± 13.7 0.003
SBP (mmHg) 130.0 (110.0e145.0) 120.0 (80.0e150.0) <0.001
DBP (mmHg) 80.0 (65.0e100.0) 80.0 (60.0e95.0) <0.001
Peak GH response (mg/L) 0.4 (0.1e4.9) 7.9 (0.1e18.0) <0.001
IGF-1 (mg/L) 132.0 (85.0e267.9) 218.5 (67.0e483.0) <0.001
IGF-1 (SDS) 2.5 (4.0 to 1.0) 1.3 (4.1 to 5.9) <0.001
PTH (pg/mL) 41.3 (31.9e75.9) 44.3 (15.6e109.0) <0.001
Total Calcium (mg/dl) 9.5 ± 0.3 9.5 ± 0.4 0.799
Corrected Calcium (mg/dL) 9.1 ± 0.3 9.0 ± 0.4 0.445
Fasting Glucose (mg/dL) 94.0 (84.0e118.0) 84.0 (61.0e243.0) <0.001
Fasting Insulin (mU/mL) 20.8 (14.4e41.9) 9.7 (4.7e46.3) <0.001
HoMA-IR 4.7 (3.4e8.7) 2.1 (0.8e20.9) <0.001
Creatinine (mg/dL) 0.8 (0.5e1.0) 0.8 (0.5e1.1) 0.178
Serum albumin (g/dL) 4.4 ± 0.3 4.5 ± 0.3 0.211
Total serum protein (g/dL) 7.9 (7.5e8.4) 7.8 (6.9e8.8) 0.001
Total cholesterol (mg/dL) 201.1 ± 39.6 170.4 ± 41.3 0.008
HDL cholesterol (mg/dL) 41.0 (32.0e59.0) 51.0 (27.0e75.0) <0.001
LDL cholesterol (mg/dL) 127.4 ± 36.9 91.7 ± 44.1 0.011
Fasting
Triglycerides (mg/dL)
141.0 (53.0e274.0) 124.0 (44.0e583.0) <0.001
AST (U/L) 29.0 (13.0e45.0) 26.5 (7.0e91.0) <0.001
ALT (U/L) 31.5 (13.0e69.0) 40.0 (6.0e202.0) <0.001
gGT (U/L) 39.5 (28.0e93.0) 31.0 (8.0e242.0) <0.001
MetS (n, %) 4 (36.4%) 18 (27.3%) 0.029
The subgroup of the consumers of 250 mL reduced-fat milk presented better
anthropometric measurements and metabolic proﬁle compared with those
consuming250mL low-fatmilk. In addition, this subgrouppresentedhigher peakGH
response and IGF-1 SDS. In particular, the peak GH response was sufﬁcient in 78.8%
consumers of 250 mL reduced-fat milk vs 27.3% consumers of 250 mL low-fat milk
(c2 ¼ 9.87; p ¼ 0.002). Results are expressed as mean ± SD or as median plus range
according to variable distributions evaluated by KolmogoroveSmirnov test. T-test or
ManneWhitney test were used to test the signiﬁcance of differences among the two
groups. The chi square (c2) test was used to determine signiﬁcance differences in
frequencydistributions ofMetS. Apvalue in bold typedenotes a signiﬁcantdifference
(p < 0.05). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; GH, growth hormone; IGF-1, insulin-like growth factor 1; IGF-1 (SDS),
insulin-like growth factor 1 standard deviation score; PTH, parathyroid hormone;
HoMA-IR, homeostasis model assessment - insulin resistance; HDL, High-density li-
poprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT,
Alanine transaminase; gGT, g-glutamyltransferase;MetS, metabolic syndrome.
Fig. 2. Different prevalence of growth hormone deﬁciency (GHD) and insulin-like growth fac
The peak GH response and IGF-1 SDS levels in the study population grouped according to
obesity the prevalence of individuals with a normal peak GH response and normal IGF-1 SDS
with those consuming different servings. Results are expressed as percentage. The chi squa
butions of GHD and IGF-1 SDS deﬁciency, respectively. GH, growth hormone; IGF-1 (SDS),
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well-known satiating effect of milk proteins, the increased faecal fat
excretion as well as the calcium appetite concept [37].
Despite the great body of evidence supporting the beneﬁcial
effects delivered by the regular consumption of milk, very little is
known about the biological mechanisms likely to be involved in the
relationships of milk and dairy foods with human health. Milk is
likely the most important source of bioavailable calcium, especially
when associated to vitamin D. Although fat-reduced milk products
tend to have low vitamin D, their vitamin D content is however
higher than that in low-fat milk products. Among its beneﬁcial
effects, bioavailable calcium has been reported to reduce fat ab-
sorption through the forming of soaps in the intestine [38]. The
independent positive association of milk consumption, speciﬁcally
250 mL reduced-fat milk, with GH status in obese individuals let us
to speculate that the preservation of somatotropic axis in obese
individuals regularly consuming milk might be one of the mecha-
nisms involved in the protective effects of milk on obesity and
obesity-related co-morbidities, likely through the effects of speciﬁc
milk nutrients, such as amino acids or lipids, on GH physiologic
secretion. In particular, amino acids, such as arginine, lysine and
ornithine, can stimulate GH release, while FFAs exert an inhibitory
control on GH secretion [9,14]. Thus, in this aspect, it is intriguing to
hypothesize that 250 mL serving provides the best association
between energy intake, fat and protein contents, and amount of
calcium and vitamin D.
Limitations of this studywarrant some consideration. Firstly, the
cross-sectional nature of this study did not allow to determine
whether any cause-and-effect relationship exists between milk
consumption and GH status. Second, in this study we could not
consider the protein for dairy, cheese, and yogurt groups. However,
previous studies have reduced the primary role of protein intake in
the positive association between milk consumption and IGF-1 [28].
In addition, as the peak GH response was higher among low-fat
compared with reduced fat milk consumers, it will be mandatory
to verify the association between GH status and fat content in milk
also including obese subjects consuming whole fat milk. Third, the
detailed nature of 7-days record could induce the misreporting of
food intake and portion sizes. However, besides to minimize the
subject recall bias, seven days has been shown to be an appropriate
length of time to accurately assess nutrient intake and effectivelytor (IGF)-1 deﬁciency according to the amount of milk consumption and degree obesity.
the amount of milk consumption and BMI. In both patients with moderate and severe
levels were higher among individuals consuming the 250 mL serving of milk compared
re (c2) test was used to determine signiﬁcance in differences in the frequency distri-
insulin-like growth factor-1 standard deviation score; BMI, body mass index.
Table 5
Bivariate proportional odds ratio models performed to assess the association of milk
consumption (yes/no) with anthropometric measures and metabolic proﬁle.
Parameters OR p value 95% IC AIC R2 adj
Gender 1.24 0.462 0.70e2.18 12.74 0.002
Age (years) 0.99 0.207 0.97e1.00 136.30 0.025
BMI (kg/m2) 0.73 <0.001 0.67e0.79 308.65 0.570
Waist circumference (cm) 0.94 <0.001 0.92e0.96 194.51 0.195
SBP (mmHg) 0.96 <0.001 0.94e0.98 83.54 0.078
DBP (mmHg) 0.97 0.017 0.95e0.99 61.12 0.027
PTH (pg/mL) 0.97 <0.001 0.95e0.98 207.28 0.288
Total Calcium (mg/dL) 8.11 <0.001 4.06e16.20 120.51 0.203
Corrected Calcium (mg/dL) 3.43 0.001 1.74e6.76 179.87 0.163
Fasting Glucose (mg/dL) 0.95 <0.001 0.94e0.97 233.68 0.352
Fasting Insulin (mU/mL) 0.90 <0.001 0.88e0.93 297.46 0.455
HoMA-IR 0.76 <0.001 0.70e0.83 285.61 0.492
Creatinine (mg/dL) 0.30 0.158 0.06e1.60 44.53 0.039
Serum albumin (g/dL) 2.42 0.069 0.92e6.35 59.64 0.014
Total cholesterol (mg/dL) 0.99 0.003 0.99e0.99 232.41 0.053
HDL cholesterol (mg/dL) 1.03 0.023 1.00e1.05 127.26 0.027
LDL cholesterol (mg/dL) 0.99 0.004 0.99e0.99 304.60 0.055
Fasting Triglycerides (mg/dL) 0.99 0.035 0.99e0.99 240.23 0.056
AST (U/L) 0.99 0.061 0.97e1.00 164.40 0.072
ALT (U/L) 0.99 0.036 0.98e0.99 182.59 0.044
gGT (U/L) 0.99 0.019 0.97e0.99 192.40 0.149
MetS (yes/no) 0.22 <0.001 0.12e0.39 41.48 0.099
Bivariate proportional odds ratio model performed to assess the association of milk
consumption (yes/no) with anthropometric measures and metabolic proﬁle. As ex-
pected, milk consumption was associated with both anthropometric measurements
and metabolic proﬁle. A p value in bold type denotes a signiﬁcant difference (p <
0.05). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; PTH, parathyroid hormone; HoMA-IR, homeostasis model assessment -
insulin resistance;HDL, High-density lipoprotein; LDL, low-density lipoprotein;AST,
aspartate aminotransferase; ALT, Alanine transaminase; gGT, g-glutamyltransfer-
ase; OR, odds ratio; AIC, Akaike Information Criterion; IC, conﬁdence interval.
Table 7
Bivariate proportional odds ratio model, adjusted for BMI, age and gender, to assess
the association of milk consumption (yes/no; model 1) and type of milk (reduced-
fat/low-fat milk; model 2), with the GH status.
OR p value 95% IC
Model 1 e Milk consumption
Peak GH response <0.001 0.105e0.285
Yes 0.60
No 0.40
IGF-1 SDS <0.001 0.023e0.659
Yes 0.58
No 0.42
Model 2 e Type of milk
Peak GH response <0.001 0.349e0.621
Reduced-fat 0.60
Low-fat 0.40
IGF-1 SDS <0.001 0.534e1.04
Reduced-fat 0.65
Low-fat 0.35
Model value ﬁttings
Model 1 Model 2
Peak GH response IGF-1 SDS Peak GH response IGF-1 SDS
AIC 242.82 238.25 173.04 194.17
R2 adj 0.14 0.13 0.44 0.38
Bivariate proportional odds ratio model performed to assess the association of milk
consumption (yes/no; model 1) and type of milk (reduced-fat/low-fat milk; model
2), with the GH status. A p value in bold type denotes a signiﬁcant difference (p <
0.05). After adjusting for BMI, age and gender, the subjects consuming milk, in
particular reduced-fat milk, have higher peak GH response and IGF-1 SDS than those
not consuming milk or consuming low-fat milk. In model 2, the model ﬁtting is
better with peak GH response covariate than IGF-1 SDS. AIC value ﬁtting and R2
adjusted for peak GH response are lower and higher, respectively, than the AIC value
ﬁtting and R2 adjusted for IGF-1 SDS, respectively. GH, growth hormone; IGF-1
(SDS), insulin-like growth factor 1 standard deviation score; OR, odds ratio; AIC,
Akaike Information Criterion; IC, conﬁdence interval.
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weekdays and weekends [39,40]. Finally, in this study we did not
investigate the possible effects of different food products/diet
regimen on the association between metabolic proﬁle and milk
consumption. In conclusion, although further studies are needed to
better deﬁne the possible involvement of milk in the ﬁne tuning of
the somatotropic axis activity in obesity, overall ﬁndings suggest a
novel positive association between milk consumption, metabolic
proﬁle and GH status in obese individuals.Table 6
Multivariate proportional odds ratio model, adjusted for BMI, age and gender, to
assess the association among three different servings of milk (125/250/375mL) with
the GH status.
Probability p value OR
Model 1 (peak GH response)
125 mL 0.32 0.086 0.78
250 mL 0.41 0.002
375 mL 0.25
Model 2 (IGF-1 SDS)
125 mL 0.23 0.026 0.41
250 mL 0.62 0.295
375 mL 0.17
Model value ﬁttings
Model 1 (peak GH response) Model 2 (IGF-1 SDS)
AIC 408.92 421.38
R2 adj 0.007 0.006
Multivariate proportional odds ratio model performed to assess the association
among three different servings of milk (125/250/375 mL) with the GH status. A p
value in bold type denotes a signiﬁcant difference (p < 0.05). After adjusting for BMI,
age and gender, the subjects consuming 250 mL presented the best GH status. AIC
value ﬁtting and R2 adjusted for peak GH response are not different, respectively,
than the AIC value ﬁtting and R2 adjusted for IGF-1 SDS, respectively. GH, growth
hormone; IGF-1 (SDS), insulin-like growth factor 1 standard deviation score; OR,
odds ratio; AIC, Akaike Information Criterion; IC, conﬁdence interval.Regardless of the pathogenetic mechanisms, this novel associ-
ation might be relevant in a context where obese individuals
commonly skip breakfast, and to drink milk is often discourage by
its saturated fat contents. The association between milk con-
sumption and GH status suggests that a growing cooperation be-
tween Nutritionists and Endocrinologists might provide a
combination key in the complex management of the obese patients
and may encourage further studies to evaluate the effects of theTable 8
Bivariate proportional odds ratio model, adjusted for BMI, age and gender, to assess
the association of 250 mL reduced-fat or 250 mL low-fat.
OR p value 95% IC
Peak GH response 0.327e1.610
250 mL reduced-fat milk 0.54 0.003
250 mL low-fat milk 0.46 0.252
Proportional odds 0.83
IGF-1 SDS 0.130 to 0.015
250 mL reduced-fat milk 0.63 <0.001
250 mL low-fat milk 0.36 0.100
Proportional odds 0.57
Model value ﬁttings
Peak GH response IGF-1 SDS
AIC 358.82 344.38
R2 adj 0.21 0.26
Bivariate proportional odds ratio model performed to assess the association of 250mL
reduced-fat or 250mL low-fat. A p value in bold type denotes a signiﬁcant difference (p
< 0.05). After adjusting for BMI, age and gender, subjects consuming 250mL reduced-
fat milk have higher peak GH response and IGF-1 SDS than those consuming 250 mL
low-fat milk. AIC value ﬁtting and R2 adjusted for peak GH response are not different,
respectively, than the AIC value ﬁtting and R2 adjusted for IGF-1 SDS, respectively. GH,
growth hormone; IGF-1 (SDS), insulin-like growth factor 1 standard deviation score;
OR, odds ratio; AIC, Akaike Information Criterion; IC, conﬁdence interval.
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